BofA analyst Michael Ryskin raised the firm’s price target on Agilent (A) to $140 from $134 and keeps a Neutral rating on the shares after Alnylam (ALNY) reported positive topline data for the phase 3 HELIOS-B trial evaluating vutrisiran in ATTR-CM that the analyst calls a “best-case scenario.” Alnylam is a known key customer of Agilent’s NASD business and Agilent would benefit from a successful launch of vutrisiran in ATTR-CM, notes the analyst, who thinks the near-term benefit could be up to a roughly $150M tailwind to sales in 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- Agilent Technologies’ AI Challenge: Balancing Innovation Risk with Regulatory Compliance
- Agilent assumed with Hold from Buy at Jefferies
- Agilent price target lowered to $125 from $135 at Barclays
- Agilent price target lowered to $134 from $145 at BofA
- Agilent price target lowered to $136 from $147 at Baird